Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387205 · ClinicalTrials.gov registry record · Phase 1
Study To Assess Long Term Safety Of Pazopanib
A Phase 1 study of Carcinoma, Renal Cell, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 188
- Enrollment target
- 19
- Study locations
NCT00387205: Completed Phase 1 study of Carcinoma, Renal Cell, sponsored by Novartis Pharmaceuticals.
NCT00387205 is a Phase 1 study of Carcinoma, Renal Cell that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 188 participants, below the 278-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (32% lower). The trial reports 19 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387205, a Phase 1 study of Carcinoma, Renal Cell, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 188 participants
- Enrollment target
- 19
- Study locations
Study Summary
This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.
Primary Outcome
To evaluate the safety assessments; adverse events, vital signs, physical examinations, electrocardiograms, multi-gated acquisition scans or echocardiograms (only for patients on pazopanib and lapatinib combination therapy), and clinical laboratory assessments.
Conditions Studied
Interventions
- DRUG Pazopanib
Study Locations (19)
Other
- Novartis Investigative Site - Lyon
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Newcastle upon Tyne
California
- Novartis Investigative Site - Duarte
- Novartis Investigative Site - Santa Monica
Colorado
- Novartis Investigative Site - Aurora
Indiana
- Novartis Investigative Site - Indianapolis
Michigan
- Novartis Investigative Site - Detroit
Minnesota
- Novartis Investigative Site - Minneapolis
New Hampshire
- Novartis Investigative Site - Lebanon
New Jersey
- Novartis Investigative Site - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2006-06-20 |
| Est. Completion | 2018-03-08 |
| Phase | Phase 1 |
What the finished NCT00387205 record still lists
NCT00387205 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 278-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Pazopanib is the first listed.
NCT00387205 lists 19 locations in 16 states (Other, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT00387205 about?
NCT00387205 is a clinical study titled "Study To Assess Long Term Safety Of Pazopanib". This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.
What is the current status of trial NCT00387205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 188 participants. The study started on 2006-06-20. Estimated completion is 2018-03-08.
What conditions does trial NCT00387205 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00387205?
The interventions under investigation include: Pazopanib (DRUG).
Who is sponsoring clinical trial NCT00387205?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00387205 being conducted?
This trial has 19 study locations across California, Colorado, Indiana, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00387205's enrollment target sits among peer trials
188 13th of 34 higher than 22 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI